Amarin Corp. Plc is a clinical-stage biopharmaceutical company. It focuses on improving the treatment of cardiovascular disease, including hypertriglyceridemia. Amarin also focusing on AMR101, a prescription-grade omega-3 fatty acid. The firm has completed two pivotal Phase 3 studies of AMR101, which include Marine and Anchor under the Special Protocol Assessment agreements with the U.S. Food and Drug Administration. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.